363 related articles for article (PubMed ID: 30905063)
21. The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit.
Selvapatt N; Ward T; Harrison L; Lombardini J; Thursz M; McEwan P; Brown A
Liver Int; 2017 Mar; 37(3):345-353. PubMed ID: 27566283
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
23. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6.
He T; Lopez-Olivo MA; Hur C; Chhatwal J
Aliment Pharmacol Ther; 2017 Oct; 46(8):711-721. PubMed ID: 28836278
[TBL] [Abstract][Full Text] [Related]
24. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings.
Rein DB; Smith BD; Wittenborn JS; Lesesne SB; Wagner LD; Roblin DW; Patel N; Ward JW; Weinbaum CM
Ann Intern Med; 2012 Feb; 156(4):263-70. PubMed ID: 22056542
[TBL] [Abstract][Full Text] [Related]
25. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
[TBL] [Abstract][Full Text] [Related]
26. Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis.
Ciaccio A; Cortesi PA; Bellelli G; Rota M; Conti S; Okolicsanyi S; Rota M; Cesana G; Mantovani LG; Annoni G; Strazzabosco M
Liver Int; 2017 Jul; 37(7):982-994. PubMed ID: 27943549
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
Goel A; Chen Q; Chhatwal J; Aggarwal R
J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
Deuffic-Burban S; Obach D; Canva V; Pol S; Roudot-Thoraval F; Dhumeaux D; Mathurin P; Yazdanpanah Y
J Viral Hepat; 2016 Oct; 23(10):767-79. PubMed ID: 27144512
[TBL] [Abstract][Full Text] [Related]
29. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.
Chhatwal J; He T; Lopez-Olivo MA
Pharmacoeconomics; 2016 Jun; 34(6):551-67. PubMed ID: 26748919
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness and cost-effectiveness of immediate versus delayed treatment of hepatitis C virus-infected patients in a country with limited resources: the case of Egypt.
Obach D; Deuffic-Burban S; Esmat G; Anwar WA; Dewedar S; Canva V; Cousien A; Doss W; Mostafa A; Pol S; Buti M; Siebert U; Fontanet A; Mohamed MK; Yazdanpanah Y
Clin Infect Dis; 2014 Apr; 58(8):1064-71. PubMed ID: 24510934
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada.
Moshyk A; Martel MJ; Tahami Monfared AA; Goeree R
J Med Econ; 2016; 19(2):181-92. PubMed ID: 26453248
[TBL] [Abstract][Full Text] [Related]
32. Assessing the cost-effectiveness of hepatitis C screening strategies in France.
Deuffic-Burban S; Huneau A; Verleene A; Brouard C; Pillonel J; Le Strat Y; Cossais S; Roudot-Thoraval F; Canva V; Mathurin P; Dhumeaux D; Yazdanpanah Y
J Hepatol; 2018 Oct; 69(4):785-792. PubMed ID: 30227916
[TBL] [Abstract][Full Text] [Related]
33. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
Kapol N; Lochid-Amnuay S; Teerawattananon Y
BMC Gastroenterol; 2016 Aug; 16(1):91. PubMed ID: 27492396
[TBL] [Abstract][Full Text] [Related]
34. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States.
McEwan P; Ward T; Yuan Y; Kim R; L'italien G
Hepatology; 2013 Jul; 58(1):54-64. PubMed ID: 23389841
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of the highly effective direct-acting antivirals in the treatment of chronic hepatitis C in Hong Kong.
Lo AO; Chan HL; Wong VW; Wong GL
J Gastroenterol Hepatol; 2017 May; 32(5):1071-1078. PubMed ID: 28449343
[TBL] [Abstract][Full Text] [Related]
36. Cost-Effectiveness of Access Expansion to Treatment of Hepatitis C Virus Infection Through Primary Care Providers.
Rattay T; Dumont IP; Heinzow HS; Hutton DW
Gastroenterology; 2017 Dec; 153(6):1531-1543.e2. PubMed ID: 29074450
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
[TBL] [Abstract][Full Text] [Related]
38. Estimating cost-effectiveness associated with all-oral regimen for chronic hepatitis C in China.
Chen H; Chen L
PLoS One; 2017; 12(4):e0175189. PubMed ID: 28380022
[TBL] [Abstract][Full Text] [Related]
39. Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis.
Lim AG; Scott N; Walker JG; Hamid S; Hellard M; Vickerman P
PLoS Med; 2021 Oct; 18(10):e1003818. PubMed ID: 34665815
[TBL] [Abstract][Full Text] [Related]
40. Improved Health Outcomes from Hepatitis C Treatment Scale-Up in Spain's Prisons: A Cost-Effectiveness Study.
Dalgic OO; Samur S; Spaulding AC; Llerena S; Cobo C; Ayer T; Roberts MS; Crespo J; Chhatwal J
Sci Rep; 2019 Nov; 9(1):16849. PubMed ID: 31727921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
